REVENUE (Tables)

3 Months Ended

Jun. 30, 2023

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the six months ended June 30, 2023, is as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2022	$	30.7	$	10.5	$	0.7	$	41.9
Plus, credit loss expense	4.3		—		—		4.3
Less, write offs	(4.4)		0.4		—		(4.0)
Balance as of June 30, 2023	$	30.6	$	10.9	$	0.7	$	42.2

Contract with Customer, Asset and Liability [Table Text Block]

	June 30, 2023		December 31, 2022
Dx accounts receivable	$	1,114.4	$	1,046.9
BLS accounts receivable	821.0		769.3
Less BLS allowance for doubtful accounts	(30.6)		(30.7)
Accounts receivable	$	1,904.8	$	1,785.5
Gross unbilled services	$	148.7	$	222.3
Less reserve for unbilled services	(10.9)		(10.5)
Unbilled services	$	137.8	$	211.8
Unearned revenue	$	349.7	$	310.6

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2023, and 2022, were as follows:

	For the Three Months Ended June 30, 2023								For the Three Months Ended June 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	23	%	—	%	—	%	23	%
Patients	10	%	—	%	—	%	10	%	9	%	—	%	—	%	9	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	35	%	—	%	—	%	35	%	37	%	—	%	—	%	37	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

	For the Six Months Ended June 30, 2023								For the Six Months Ended June 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	25	%	—	%	—	%	25	%	22	%	—	%	—	%	22	%
Patients	10	%	—	%	—	%	10	%	7	%	—	%	—	%	7	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	7	%	—	%	—	%	7	%
Third party	35	%	—	%	—	%	35	%	41	%	—	%	—	%	41	%
Total Dx revenues by payer	78	%	—	%	—	%	78	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	9	%	9	%	4	%	22	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the U.S. were $2,537.0 (83.6%) and $2,449.5 (83.8%) for the three months ended June 30, 2023, and 2022, respectively, and for the six months ended June 30, 2023, and 2022, were $5,094.4 (83.9%) and $5,061.6 (83.4%), respectively.